9/19/2025

Madison Investments, an investment advisor, released its “Madison Mid Cap Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund (Class Y) returned 5.2% compared to the 8.5% increase for the Russell Midcap Index. In addition, please check the fund’s top five holdings to know […]

Source: Yahoo

9/17/2025

For this year, Medpace expects that its revenues will increase by 17.1%, which is an excellent growth rate. Read why MEDP stock is a Buy.

Source: SeekingAlpha

9/15/2025

Medpace (MEDP) reached $496.41 at the closing of the latest trading day, reflecting a +1.18% change compared to its last close.

Source: Yahoo

9/12/2025

Apart from artificial intelligence and software stocks, the list has no less than 15 health care names, indicating that the sector has participated in the stock market's advance. Travere Therapeutics gapped up 26% on Wednesday after a positive regulatory update. The U.S. Food and Drug Administration determined Travere would no longer need an advisory committee for its supplementary new drug application for a kidney-disease treatment.

Source: Yahoo

9/12/2025

Hasbro, Robinhood, Interactive Brokers, Celsius, and Medpace are top non-tech Nasdaq stocks showing strong growth and robust earnings potential in 2025.

Source: Yahoo

9/11/2025

Non-tech Nasdaq standouts like HAS, HOOD, IBKR, CELH and MEDP are fueling 2025's index surge.

Source: Yahoo

9/9/2025

The latest trading day saw Medpace (MEDP) settling at $492.09, representing a +1.05% change from its previous close.

Source: Yahoo

9/5/2025

We came across a bullish thesis on Medpace Holdings, Inc. on Rocky&Turner’s Substack by James Emanuel. In this article, we will summarize the bulls’ thesis on MEDP. Medpace Holdings, Inc. ‘s share was trading at $475.51 as of August 29th. MEDP’s trailing and forward P/E were 35.33 and 34.84 respectively according to Yahoo Finance. Medpace Holdings (Nasdaq: […]

Source: Yahoo

9/2/2025

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Source: Yahoo

8/29/2025

Earnings results of our AI Basket members have been generally positive, though stock price reactions haven't been overwhelmingly so. But a few names experienced explosive moves on earnings.

Source: SeekingAlpha

8/28/2025

Veeva Systems' second-quarter earnings and revenues beat estimates, margins expand and raised FY26 outlook lifts shares higher.

Source: Yahoo

8/27/2025

Read here for an in-depth analysis and insights on Fundsmith's $23.02B portfolio shift: new stakes, exits, and top positions like Meta and Microsoft.

Source: SeekingAlpha

8/22/2025

Medpace currently trades at $450.01 and has been a dream stock for shareholders. It’s returned 266% since August 2020, more than tripling the S&P 500’s 85.3% gain. The company has also beaten the index over the past six months as its stock price is up 30.7% thanks to its solid quarterly results.

Source: Yahoo

8/19/2025

Health care stock Medpace Holdings soared to an all-time high after second-quarter results. Shares are in a 5% buy zone,.

Source: Yahoo

8/19/2025

NeuroOne stock rallies after FDA clears its OneRF system, a minimally invasive solution targeting severe facial pain, scheduled to launch in late 2025.

Source: Yahoo

8/18/2025

Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Source: Yahoo

8/15/2025

Biotech stocks are performing well in the stock market in August and a few in the IBD 50 have formed bases with clear buy points.

Source: Yahoo

8/14/2025

A Relative Strength Rating upgrade for Tempus AI shows improving technical performance. Will it continue?

Source: Yahoo

8/4/2025

Source: SeekingAlpha

7/31/2025

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Source: Yahoo